Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
This investigation aims to examine the safety and effectiveness of Xeljanz in post-marketing clinical settings when it is administered chronically to patients with ulcerative colitis, based on the approval conditions.
Age
0–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with ulcerative colitis treated with XELJANZ
Patients naive to XELJANZ in the treatment of ulcerative colitis
